Literature DB >> 33309638

The Angiotensin-(1-12)/Chymase axis as an alternate component of the tissue renin angiotensin system.

Carlos M Ferrario1, Leanne Groban2, Hao Wang2, Che Ping Cheng3, Jessica L VonCannon4, Kendra N Wright4, Xuming Sun2, Sarfaraz Ahmad4.   

Abstract

The identification of an alternate extended form of angiotensin I composed of the first twelve amino acids at the N-terminal of angiotensinogen has generated new knowledge of the importance of noncanonical mechanisms for renin independent generation of angiotensins. The human sequence of the dodecapeptide angiotensin-(1-12) [N-Asp1-Arg2-Val3-Tyr4-Ile5-His6-Pro7-Phe8-His9-Leu10-Val1-Ile12-COOH] is an endogenous substrate that in the rat has been documented to be present in multiple organs including the heart, brain, kidney, gut, adrenal gland, and the bone marrow. Newer studies have confirmed the existence of Ang-(1-12) as an Ang II-forming substrate in the blood and heart of normal and diseased patients. Studies to-date document that angiotensin II generation from angiotensin-(1-12) does not require renin participation while chymase rather than angiotensin converting enzyme shows high catalytic activity in converting this tissue substrate into angiotensin II directly.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Angiotensin I; Angiotensin II; Angiotensin peptides; Angiotensin-(1–12); Angiotensin-converting enzyme; Angiotensinogen; Chymase; Metabolism; Renin; Renin-angiotensin system

Mesh:

Substances:

Year:  2020        PMID: 33309638      PMCID: PMC8127338          DOI: 10.1016/j.mce.2020.111119

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.369


  111 in total

Review 1.  Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate.

Authors:  Sarfaraz Ahmad; Jasmina Varagic; Leanne Groban; Louis J Dell'Italia; Sayaka Nagata; Neal D Kon; Carlos M Ferrario
Journal:  Curr Hypertens Rep       Date:  2014-05       Impact factor: 5.369

2.  Effects of the selective chymase inhibitor TEI-F00806 on the intrarenal renin-angiotensin system in salt-treated angiotensin I-infused hypertensive mice.

Authors:  Tuba M Ansary; Maki Urushihara; Yoshihide Fujisawa; Sayaka Nagata; Hidenori Urata; Daisuke Nakano; Hitomi Hirofumi; Kazuo Kitamura; Shoji Kagami; Akira Nishiyama
Journal:  Exp Physiol       Date:  2018-09-14       Impact factor: 2.969

3.  Evidence for the existence of a family of biologically active angiotensin I-like peptides in the dog central nervous system.

Authors:  A Husain; F M Bumpus; R R Smeby; K B Brosnihan; M C Khosla; R C Speth; C M Ferrario
Journal:  Circ Res       Date:  1983-04       Impact factor: 17.367

4.  Noncanonical Mechanisms for Direct Bone Marrow Generating Ang II (Angiotensin II) Predominate in CD68 Positive Myeloid Lineage Cells.

Authors:  Tomohisa Yamashita; Sarfaraz Ahmad; Kendra N Wright; Drew J Roberts; Jessica L VonCannon; Hao Wang; Leanne Groban; Louis J Dell'Italia; Carlos M Ferrario
Journal:  Hypertension       Date:  2019-12-09       Impact factor: 10.190

Review 5.  Novel roles of nuclear angiotensin receptors and signaling mechanisms.

Authors:  TanYa M Gwathmey; Ebaa M Alzayadneh; Karl D Pendergrass; Mark C Chappell
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-14       Impact factor: 3.619

6.  High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes.

Authors:  Vivek P Singh; Bao Le; Vadiraja B Bhat; Kenneth M Baker; Rajesh Kumar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-05-04       Impact factor: 4.733

7.  Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial.

Authors:  Hans-Dirk Duengen; Raymond J Kim; Doron Zahger; Katia Orvin; Ran Kornowski; Dan Admon; Jiri Kettner; Avraham Shimony; Christiane Otto; Michael Becka; Friederike Kanefendt; Andres Iniguez Romo; Tal Hasin; Petr Ostadal; Gonzalo Calvo Rojas; Michele Senni
Journal:  Am Heart J       Date:  2020-01-25       Impact factor: 4.749

8.  Chymase inhibition protects diabetic rats from renal lesions.

Authors:  Mei Zhang; Wen Huang; Jing Bai; Xiaodong Nie; Wen Wang
Journal:  Mol Med Rep       Date:  2016-05-10       Impact factor: 2.952

9.  Role of the Renin Angiotensin System in Blood Pressure Allostasis-induced by Severe Food Restriction in Female Fischer rats.

Authors:  Aline Maria Arlindo de Souza; Crystal A West; Aline Rezende Ribeiro de Abreu; Amrita V Pai; Laura Batista Tavares Mesquita; Hong Ji; Deoclécio Chianca; Rodrigo Cunha Alvim de Menezes; Kathryn Sandberg
Journal:  Sci Rep       Date:  2018-07-09       Impact factor: 4.379

10.  Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis.

Authors:  Vivek P Singh; Bao Le; Renu Khode; Kenneth M Baker; Rajesh Kumar
Journal:  Diabetes       Date:  2008-10-01       Impact factor: 9.461

View more
  3 in total

1.  Immunoneutralization of human angiotensin-(1-12) with a monoclonal antibody in a humanized model of hypertension.

Authors:  Carlos M Ferrario; Jessica L VonCannon; Jie Zhang; Jorge P Figueroa; Kendra N Wright; Leanne Groban; Amit Saha; J Wayne Meredith; Sarfaraz Ahmad
Journal:  Peptides       Date:  2021-12-18       Impact factor: 3.750

Review 2.  The renin-angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts.

Authors:  Carlos M Ferrario; Leanne Groban; Hao Wang; Xuming Sun; Jessica L VonCannon; Kendra N Wright; Sarfaraz Ahmad
Journal:  Kidney Int Suppl (2011)       Date:  2022-03-18

3.  Heart Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 Gene Expression Associated With Male Sex and Salt-Sensitive Hypertension in the Dahl Rat.

Authors:  Kirsti Ytrehus; Stian Ludvigsen; Costantino Mancusi; Eva Gerdts; Giovanni de Simone
Journal:  Front Physiol       Date:  2021-07-19       Impact factor: 4.566

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.